Both in Pharmaceuticals
Arvinas vs Monopar Therapeutics
Over the past year ARVN returned −20.2% and MNPR returned −11.8%; their daily moves had a correlation of 0.32.
ARVN −20.2% MNPR −11.8%Growth of $1, one year, split-adjusted
| Metric | ARVN | MNPR |
|---|---|---|
| Price | $7.58 | $70.52 |
| Market cap | $495.6M | $473.3M |
| Today | +1.75% | −1.84% |
| 1 month | +1.1% | −11.8% |
| 6 months | −22.8% | +40.7% |
| Year to date | −36.1% | +8.0% |
| 1 year | −21.5% | −13.2% |
| Revenue growth (YoY) | +1014.7% | — |
| Gross margin | 96.4% | — |
| Net margin | 67.8% | — |
| P/E (TTM) | 53.3× | — |
| Price / sales | 1.6× | — |
| Net cash | $567.6M | $134.3M |
| Dividend yield | — | — |
| Volatility (60d) | 48.4% | 48.9% |
| Short % of float | 10.2% | 23.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).